PharVision Advisers’s Tanger SKT Stock Holding History

PharVision Advisers’s Portfolio SKT Stock Details SKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,078	Closed	-$307K	–	974
2025 Q3	$307K	Buy	+9,078	New	+$296K	0.17%	213
2025 Q2	–	Sell	-9,238	Closed	-$312K	–	414
2025 Q1	$312K	Buy	+9,238	New	+$310K	0.43%	87

Other funds holding SKT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PharVision Advisers's SKT Position: Q4 2025 in Review

PharVision Advisers sold out of Tanger (SKT) in Q4 2025, closing a stake of 9,078 shares — an estimated $307K sold.

PharVision Advisers first reported a position in SKT in Q1 2025 and held it in 2 quarters. The position peaked at $312K in Q1 2025. 342 funds tracked by Wall St. Rank hold SKT as of Q4 2025.

PharVision Advisers reported no remaining Tanger position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 9,078 Tanger shares in Q4 2025, an estimated $307K.
PharVision Advisers first reported a position in Tanger in Q1 2025 and held it in 2 quarters.
PharVision Advisers's Tanger position peaked at $312K in Q1 2025.
342 funds tracked by Wall St. Rank held Tanger as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.